Abstracts tagged "registry"

Abstract Number: 580 • 2018 ACR/ARHP Annual Meeting
Clinical Effectiveness of Tofacitinib 11mg Once Daily (QD) Versus Tofacitinib 5mg Twice Daily (BID) in the Corrona US RA Registry
Stanley Cohen¹, Heather J Litman², Connie Chen³, Tatjana Lukic³, Ann Madsen³, Liza Takiya⁴, Kimberly J Dandreo², Taylor Blachley² and Jeffrey Greenberg², ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Corrona LLC, Waltham, MA, ³Pfizer Inc, New York, NY, ⁴Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA, originally approved at 5 mg twice daily (BID). In 2016, an extended-release…
Abstract Number: 606 • 2018 ACR/ARHP Annual Meeting
Similiar Efficacy of Tofacinitib on Disease Activity in Rheumatoid Arthritis Patients with and without Previous Biologicals; Results from the Turkbio Regıstry
Berrin Zengin¹, Nevsun Inanc², Servet Akar³, Gerçek Can¹, Ediz Dalkiliç⁴, Abdurrahman Tufan⁵, Soner Senel⁶, Suleyman Serdar Koca⁷, Handan Yarkan¹, Yavuz Pehlivan⁸, Zeynep Erturk⁹, Berna Goker⁵, Haner Direskeneli², Merih Birlik¹, Nurullah Akkoc¹⁰ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ²Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ³Faculty of Medicine, Department of Rheumatology, Izmir Katip Celebi University, Izmir, Turkey, ⁴Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, ⁵Internal Medicine-Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey, ⁶Rheumatology, Kayseri Erciyes University, Faculty of Medicine, Kayseri, Turkey, ⁷Rheumatology, Firat University Faculty of Medicine, Elazığ, Turkey, ⁸Rheumatology, Uludag University, Faculty of Medicine, Bursa, Turkey, ⁹Rheumatology, Marmara University Faculty of Medicine, istanbul, Turkey, ¹⁰Rheumatology, İzmir, Turkey, İzmir, Turkey
Background/Purpose: Tofacitinib, a JAK3 inhibitor has been used to treat patients with rheumatoid arthritis (RA) in Turkey since 2015. The aim of this study was…
Abstract Number: 628 • 2018 ACR/ARHP Annual Meeting
Longitudinal Changes in Relative Market Share Proportions of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Descriptive Data from the Ontario Best-Practice Research Initiative Database
Elliot Hepworth¹, Mohammad Movahedi², Emmanouil Rampakakis³, Reza Mirza¹, Arthur Lau⁴, Angela Cesta⁵, Janet E. Pope⁶ and Claire Bombardier⁷, ¹Department of Internal Medicine, McMaster University, Hamilton, ON, Canada, ²JSS Medical Research, St-Laurent, QC, Canada, ³JSS Medical Research, Montreal, QC, Canada, ⁴50 Charlton Avenue East, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁵Ontario Best Practices Research Initiative, University Health Network, Toronto, ON, Canada, ⁶Department of Medicine, University of Western Ontario, London, ON, Canada, ⁷Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: For patients with Rheumatoid Arthritis (RA) who do not achieve adequate clinical response with combined conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs), the next…
Abstract Number: 629 • 2018 ACR/ARHP Annual Meeting
Real-World Use of Tofacitinib Compared with Tumor Necrosis Factor Inhibitors in a Cohort of 211 Patients with Rheumatoid Arthritis: Data from a Drug-Based Registry Study in Taiwan
Song-Chou Hsieh¹, Yi-Hsing Chen², Wei-Sheng Chen³, Wen-Chan Tsai⁴, Jui-Chieh Hu⁵, Hsiang-Cheng Chen⁶, Jack Mardekian⁷ and Chacun Lai⁸, ¹National Taiwan University Hospital, Taipei, Taiwan, ²Taichung Veterans General Hospital, Taichung City, Taiwan, ³Taipei Veterans General Hospital, Taipei, Taiwan, ⁴Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ⁵Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ⁶National Defense Medical Center & Tri-Services General Hospital, Taipei, Taiwan, ⁷Pfizer Global Biometrics & Data Management, NY, NY, ⁸Pfizer PFE Limited, New Taipei, Taiwan
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Tofacitinib was approved in December 2014 for RA under Taiwan’s National Health…
Abstract Number: 1641 • 2018 ACR/ARHP Annual Meeting
Spa-Net: A Disease-Specific Integrated Ehealth System and Quality Registry for Spondyloarthritis in Daily Practice in the Netherlands
Casper Webers^1,2, Esther Beckers^1,2, Yvonne van Eijk-Hustings^1,2, Harald Vonkeman³, Mart van de Laar³, Piet van Riel⁴, Monique Efde⁵, Annelies Boonen^1,2 and Astrid van Tubergen^1,2, ¹Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ²Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, Netherlands, ³Department of Rheumatology, Medisch Spectrum Twente, Enschede, Netherlands, ⁴Department of Rheumatology, Bernhoven, Uden, Netherlands, ⁵Department of Rheumatology, VieCuri Medical Center, Venlo, Netherlands
Background/Purpose: Regular and personalised monitoring of disease activity, functioning, medication use and side effects is essential to improve and maintain patients’ health-related quality of life…
Abstract Number: 2856 • 2018 ACR/ARHP Annual Meeting
Do Patients with Moderate or High Disease Activity Escalate RA Therapy According to Treat-to-Target Principles? Results from the Acr’s RISE Registry
Huifeng Yun¹, Lang Chen¹, Fenglong Xie¹, Himanshu Patel², Natalie Boytsov², Xiang Zhang² and Jeffrey R. Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Routine measurement of RA disease activity and adjustment of drug therapy to attain remission or low disease activity is recommended by the ACR and…
Abstract Number: 2870 • 2018 ACR/ARHP Annual Meeting
Thresholds for Disease Activity Measures DAS28, CDAI, and RAPID3 Do Not Align with Clinical Practice Patterns of Rheumatoid Arthritis (RA) Disease Management Decisions
Brian C. Sauer¹, Chia-Chen Teng, MS¹, Neil A. Accortt², David H. Collier², Tzu-Chieh Lin² and Grant W. Cannon¹, ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Treatment guidelines recommend using disease activity measures (DAMs) to guide RA therapy, but DAM use in real-world treatment decisions is not defined. We…
Abstract Number: 1423 • 2017 ACR/ARHP Annual Meeting
Patterns of Prednisone Use in US Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine Clinical Practice
Dimitrios A. Pappas¹, Carol J. Etzel², Jennie Best³, Steve Zlotnick³, Taylor Blachley², Gioia Persuitte² and Joel Kremer⁴, ¹Columbia University, New York, NY, ²Corrona, LLC, Southborough, MA, ³Genentech, Inc., South San Francisco, CA, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: There are limited data regarding the impact of tocilizumab (TCZ) treatment on prednisone use in patients with rheumatoid arthritis (RA). The objective of this…
Abstract Number: 1472 • 2017 ACR/ARHP Annual Meeting
Body Mass Index Does Not Affect Response to Rituximab in Patients with Rheumatoid Arthritis: Results from Turkbio Registry
Suleyman Serdar Koca¹, Ahmet Karatas², Burak Oz³, Ediz Dalkilic⁴, Gerçek Can⁵, Yavuz Pehlivan⁶, Ayten Yazici⁷, Nevsun Inanc⁸, Ayse Cefle⁹, Zeypen Erturk¹⁰, Servet Akar¹¹, Soner Senel¹², Merih Birlik¹³, Nurullah Akkoc¹⁴ and Fatos Onen¹⁵, ¹Department of Rheumatology, Firat University School of Medicine, Elazig, Turkey, ²Department of Rheumatology, Firat University, School of Medicine, Rheumatology, Elazig, Turkey, ³Rheumatology, Firat University, School of Medicine, Rheumatology, Elazig, Turkey, ⁴Department of Internal Medicine, Division of Rheumatology, Uludag University, School of Medicine, Rheumatology, Bursa, Turkey, ⁵Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ⁶Department of Rheumatology, Uludag University, Bursa, Turkey, ⁷Rheumatology, Kocaeli University, Kocaeli, Turkey, ⁸Departement of İnternal Medicine, Division of Rheumatology, Marmara University, Istanbul, Turkey, ⁹Rheumatology, Kocaeli University, School of Medicine, Rheumatology, Kocaeli, Turkey, ¹⁰Department of Rheumatology, Marmara Univeristy School of Medicine, Istanbul, Turkey, ¹¹Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, ¹²Rheumatology, Kayseri Erciyes University, School of Medicine, Rheumatology, Kayseri, Turkey, ¹³Department of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ¹⁴Rheumatology, Private Practice, Rheumatology, İzmir, Turkey, ¹⁵Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey
Background/Purpose: Adipose tissue produces several inflammatory mediators. Thus, obesity affects the disease course and the responses to the anti-rheumatic agents in inflammatory diseases. Several previous…
Abstract Number: 2366 • 2017 ACR/ARHP Annual Meeting
High Uric Acid As a Risk Factor for Cardiovascular Diseases in Rheumatoid Arthritis Patients
Adeeba Al-Herz¹, Ali Aldei¹, Khulood Saleh², Adel Al-Awadhi³, Waleed Al-Kandari², Eman Hasan⁴, Aqeel Ghanem⁵, Mohammad Hussain⁴, Ibrahim Nahar⁵, Fatemah Abutiban⁶, Ahmad Alenizi⁶, Yaser Ali⁵, Hebah Alhajeri⁵, Sawsan Hayat⁵, Ahmad Khadrawy², Ammad Fazal², Khaled Mokaddem¹, Agaz Zaman⁵, Ghada Mazloum⁵, Youssef Bartella¹, Sally Hamed¹, Ramia Alsouk⁶ and Ahmed Al-Saber⁷, ¹Rheumatology, Al-Amiri Hospital, Kuwait city, Kuwait, ²Rheumatology, Farwania Hospital, Farwania, Kuwait, ³Faculty of Medicine, Kuwait, Kuwait, ⁴Al-Amiri Hospital, Kuwait city, Kuwait, ⁵Rheumatology, Mubarak Al-Kabeer Hospital, Hawally, Kuwait, ⁶Rheumatology, Jahra Hospital, Jahra, Kuwait, ⁷Department of Mathematics, Kuwait Technical College, Kuwait city, Kuwait
Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of cardiovascular diseases (CVD). It is unclear whether an elevated serum uric acid (UA) further increases…
Abstract Number: 2665 • 2017 ACR/ARHP Annual Meeting
Mortality in an Early Diffuse Cutaneous Systemic Sclerosis Cohort—Data from the Prospective Registry for Early Systemic Sclerosis
Tracy M. Frech¹, Shervin Assassi², Elana J. Bernstein³, Flavia V. Castelino⁴, Robyn T. Domsic⁵, Jessica K. Gordon⁶, Faye Hant⁷, Monique Hinchcliff⁸, Bernie LaSalle⁹, Victoria K. Shanmugam¹⁰, Virginia D. Steen¹¹ and Dinesh Khanna¹², ¹Division of Rheumatology, University of Utah, Salt Lake City, UT, ²University of Texas McGovern Medical School, Houston, TX, ³Department of Medicine, Division of Rheumatology, Columbia University, New York, NY, ⁴Rheumatology, Allergy, Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁸Department of Medicine Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁹University of Utah, Salt Lake City, UT, ¹⁰Rheumatology, The George Washington University, Washington, DC, ¹¹Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ¹²University of Michigan, Ann Arbor, MI
Background/Purpose: The Prospective Registry of Early Systemic Sclerosis (PRESS) cohort is an early diffuse cutaneous systemic sclerosis (dcSSc) that provides an opportunity to assess the…
Abstract Number: 471 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients Resistant to Biologic Therapy, Are They Different?
Adeeba Al-Herz¹, Aqeel Ghanem², Khulood Saleh³, Adel Al-Awadhi⁴, Waleed Al-Kandari³, Eman Hasan⁵, Mohammad Hussain⁵, Ibrahim Nahar², Fatemah Abutiban⁶, Ahmad Alenizi⁶, Yaser Ali², Ali Aldei¹, Hebah Alhajeri², Sawsan Hayat², Ahmad Khadrawy³, Ammad Fazal³, Khaled Mokaddem¹, Agaz Zaman², Ghada Mazloum², Youssef Bartella¹, Sally Hamed¹, Ramia Alsouk⁶ and Ahmed Al-Saber⁷, ¹Rheumatology, Al-Amiri Hospital, Kuwait city, Kuwait, ²Rheumatology, Mubarak Al-Kabeer Hospital, Hawally, Kuwait, ³Rheumatology, Farwania Hospital, Farwania, Kuwait, ⁴Faculty of Medicine, Kuwait, Kuwait, ⁵Al-Amiri Hospital, Kuwait city, Kuwait, ⁶Rheumatology, Jahra Hospital, Jahra, Kuwait, ⁷Department of Mathematics, Kuwait Technical College, Kuwait city, Kuwait
Background/Purpose: Patients with rheumatoid arthritis (RA) may fail to respond to biologic therapy. We study patients who are resistant to different classes of biologic agents…
Abstract Number: 1580 • 2016 ACR/ARHP Annual Meeting
Impact of Rituximab on Patient-Reported Outcomes in Patients with Rheumatoid Arthritis from the US Corrona Registry
Leslie R Harrold¹, Ani John², Jennie Best², Steve Zlotnick², Chitra Karki³, YouFu Li⁴, Jeffrey D. Greenberg⁵ and Joel Kremer⁶, ¹UMass Medical School, Worcester, MA, ²Genentech, Inc., South San Francisco, CA, ³Corrona, LLC, Southborough, MA, ⁴University of Massachusetts Medical School, Worcester, MA, ⁵New York University School of Medicine, New York, NY, ⁶The Center for Rheumatology, Albany Medical College, Albany, NY
Background/Purpose: Patients with rheumatoid arthritis (RA) experience diminished quality of life and increased disability. Patient-reported outcomes (PROs) are important measures of response to therapy in…
Abstract Number: 1722 • 2016 ACR/ARHP Annual Meeting
Predictors of Achieving Remission Among Patients with Psoriatic Arthritis Prescribed TNF Inhibitors
Alexis Ogdie¹, J. Lynn Palmer², Jeffrey D. Greenberg³, Leslie R. Harrold⁴, Daniel H. Solomon⁵, Arthur Kavanaugh⁶, Joel Kremer⁷, Philip J Mease⁸ and Jeffrey R. Curtis⁹, ¹Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ²Corrona Research Foundation, Albany, NY, ³New York University School of Medicine, New York, NY, ⁴University of Massachusetts Medical School, Worcester, MA, ⁵Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶University of California San Diego, La Jolla, CA, ⁷The Center for Rheumatology, Albany Medical College, Albany, NY, ⁸Rheumatology and Internal Medicine, Swedish Medical Center and University of Washington, Seattle, WA, ⁹Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease with varied response to therapy. We examined predictors of remission at one year among patients with PsA…
Abstract Number: 2500 • 2016 ACR/ARHP Annual Meeting
Prevalence of Sustained Remission in Patients with Rheumatoid Arthritis in Sweden. Impact of Criteria Sets and Early Treatment, a Nationwide Register Study in Sweden
Jon T. Einarsson¹, Minna Willim¹, Sofia Ernestam^2,3, Tore Saxne¹, Pierre Geborek¹ and Meliha C. Kapetanovic¹, ¹Lund University, Skane University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, ²Clinical Epidemiology unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ³Centre of Rheumatology, Stockholm County Council, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: The Swedish Society for Rheumatology guidelines recommend remission as treatment goal for patients with rheumatoid arthritis (RA). The Swedish quality registry (SRQ) is a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].